A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Cystinosis.
- Conditions
- Nephropathic cystinosismetabolic disorder in which the transport of cystine out of the lysosomes is abnormal10000546
- Registration Number
- NL-OMON44053
- Lead Sponsor
- Raptor Pharmaceuticals Europe BV
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 5
Male and female subjects must completed the last visit of Study RP103-03 and be willing to continue on RP103 treatment.;Or for patients who did not complete the RP103-03 study:;Male or female subject with a documented diagnosis of nephropathic cystinosis.
Subject must be on a stable dose of Cystagon® at least 21 days prior to Screening.
Within the last 6 months, no clinically significant change from normal in liver function tests [i.e., 1.5 times ULN for ALT and AST, and/or 1.5 times ULN for total bilirubin] and renal function [i.e., estimated GFR (corrected for body surface area)] at Screening as determined by the Investigator.
Subject must have an estimated GFR (corrected for body surface area) > 30 mL/minute/1.73 m2.
Sexually active female subjects of childbearing potential (i.e., not surgically sterile [tubal ligation, hysterectomy, or bilateral oophorectomy] or at least 2 years naturally postmenopausal) must agree to utilize the same acceptable form of contraception from Screening through completion of the study. The acceptable forms of contraception for this study include hormonal contraceptives (oral, implant, transdermal patch, or injection) at a stable dose for at least 3 months prior to Screening, barrier (spermicidal condom, diaphragm with spermicide), IUD, or a partner who has been vasectomized for at least 6 months. For pre-pubescent children, a documented attestation of abstinence from their parent or guardian will be acceptable.
Subject must be willing and able to comply with the study restrictions and requirements.
Subject or their parent or guardian must provide written informed consent and assent (where applicable) prior to participation in the study.
Patients enrolled in the previous Study RP103-03 who did not complete their last scheduled Study visit or who do not wish to continue on treatment with RP103.;Subjects with current history of the following conditions or any other health issues that make it, in the opinion of the Investigator, unsafe for them to participate:
- Inflammatory bowel disease (if currently active) or prior resection of small intestine;
- Heart disease (e.g., myocardial infarction, heart failure, unstable arrhythmias, or poorly controlled hypertension) 90 days prior to Screening;
- Active bleeding disorder 90 days prior to Screening;
- History of malignant disease within the last 2 years.
Subject with a hemoglobin level of < 10 g/dL at Screening or, in the opinion of the Investigator, a hemoglobin level that would make it unsafe for the subject to participate.
Subjects with known hypersensitivity to cysteamine and penicillamine.
Female subjects who are nursing, planning a pregnancy, known or suspected to be pregnant, or with a positive serum pregnancy screen.
Subjects who have a made a blood donation within 30 days of Screening.
Subjects who, in the opinion of the Investigator, are not able or willing to comply with the protocol.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To assess safety and tolerability of RP103 using safety data collected during<br /><br>the study (adverse events, physical exams, vital signs, VAS swallowing<br /><br>assessments, ECG and clinical laboratory testing).</p><br>
- Secondary Outcome Measures
Name Time Method <p>To assess the steady-state pharmacokinetics (PK) of RP103 using trough plasma<br /><br>cysteamine concentrations 0.5 hours post-dose and to assess the steady-state<br /><br>pharmacodynamics (PD) of RP103 using WBC cystine content meastured 0.5 hours<br /><br>post-dose.</p><br>